Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT06186843 Recruiting - Hypertension Clinical Trials

Plant-based Diet for Kidney Transplant Recipients

Start date: February 29, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate cardiometabolic and inflammatory parameters in kidney transplant recipients after transitioning to a plant-based diet (PBD). The main aims of the study are as follows: - To test the feasibility of transiting renal allograft recipients who are > 3 months post-transplant to a PBD - To study the effect of a PBD on cardiometabolic parameters in kidney transplant recipients - To assess the effect of a PBD on peripheral blood Th17/Treg ratio and systemic inflammation in kidney transplant recipients Participants will be asked to: - Complete a 2-week investigator-designed PBD transition program - Follow a PBD for a minimum of 16 weeks - Consent for blood draws, urine samples, and fecal samples along with physical exams - Complete intermittent food frequency questionnaires and quality of life questionnaires - Periodically meet with investigators and other study participants Researchers will compare baseline measurements with future measurements for each participant.

NCT ID: NCT06186713 Completed - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension on Prognosis of Acute Myocardial Infarction Patients With Reduced Left Ventricular Function

STIMULATE
Start date: March 30, 2023
Phase:
Study type: Observational

Pulmonary hypertension (PH) has a negative effect on acute myocardial infarction (AMI) patients and appears to be closely associated with reduced left ventricular function. However, its impact on AMI patients with reduced left ventricular function remains unclear. This retrospective study included AMI patients with reduced left ventricular function to investigate the prognostic value of PH in this specific type of patient. Meanwhile, a nomogram would be established basing on the identified independent risk factors, hoping to provide a novel risk stratification for them.

NCT ID: NCT06186102 Recruiting - Obesity Clinical Trials

Polyamine Treatment in Elderly Patients With Coronary Artery Disease

PolyCAD
Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.

NCT ID: NCT06183671 Recruiting - Clinical trials for Resistant Hypertension

JX09 SAD/MAD in Healthy Participants

Start date: January 18, 2024
Phase: Phase 1
Study type: Interventional

This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09 when administered to healthy adult subjects.

NCT ID: NCT06181409 Not yet recruiting - Clinical trials for Advanced Chronic Liver Disease

Diagnosing and Monitoring Portal Hypertension Non-invasively Using Spleen Stiffness Measurement in Patients With Advanced Chronic Liver Disease: a Prospective Cohort Study

Start date: December 2023
Phase:
Study type: Observational

The goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease. The main question it aims to answer are: - what are the cut-off values for non-invasive tests (NITs) (including LSM, SSM) that predict the presence and occurrence of hepatic decompensation in individuals with advanced chronic liver disease? Participants will undergo regular study visits involving non-invasive tests (LSM, SSM) and assessments to monitor hepatic decompensation over the study period.

NCT ID: NCT06177678 Not yet recruiting - Ocular Hypertension Clinical Trials

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Start date: February 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study was to explore the efficacy and safety of the weekly intraocular pressure change of the TFC-003 group and the dorzolamid/timolol combination group in patients with primary open-angle glaucoma or ocular hypertension.

NCT ID: NCT06176118 Not yet recruiting - Clinical trials for Pulmonary Arterial Hypertension

Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension

Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Based on existing literature and clinical trials, 2- hydroxbenzylamine (2-HOBA) has clear impact on mechanisms that much of the international field of pulmonary hypertension (PH) research agrees are central to disease progression. The investigator's preliminary data and Phase I studies demonstrate not only a clear positive impact on reducing pulmonary vascular resistances in Group I and II PH, and both cytokine and molecular biomarkers of disease, but also indicated the potential for a substantial positive effect on heart function under load stress. In this Phase II project, investigators will test the safety and efficacy of 2-HOBA in PH patients, improving the function of the right ventricle under stress in a large animal model, and effectiveness in the context of standard-of-care in mouse models and large animals, to establish the remaining data needed to proceed to commercialization.

NCT ID: NCT06175793 Recruiting - Hypertension Clinical Trials

ASPIRE: Adapting Self-Blood Pressure Monitoring to Reduce Health Disparities

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to implement a pilot focusing on developing training manuals and materials for patients and the clinical team to ensure our intervention is delivered consistently and systematically for each patient.

NCT ID: NCT06175663 Recruiting - Hypertension Clinical Trials

Hyperintense: Midlife Hypertension and the Brain

Start date: July 6, 2021
Phase:
Study type: Observational

Cerebral small vessel disease (SVD) describes a set of pathologies affecting the smallest blood vessels in the brain. SVD contributes to up to a fifth of ischemic and hemorrhagic strokes en is the main vascular cause of dementia. On MRI, SVD is marked by different types of lesions, including white matter abnormalities, and small infarcts and hemorrhages. Recent studies indicate that SVD develops slowly over the years, starting presumably decades before the typical MRI lesions become apparent. High blood pressure plays an important role in the development of SVD MRI lesions. However, it remains unclear exactly how hypertension leads to vascular pathology. To gain more insight into how hypertension leads to SVD it is important to study mechanisms in individuals (largely) free of SVD, that is before midlife. Therefore, the investigators aim to examine abnormalities in brain (micro) structure and vascular function in young patients with hypertension. Furthermore, the investigators aim to determine the effects of blood pressure increase and subsequent blood pressure reduction during a period of withdrawal and restart of blood pressure lowering drugs on brain (micro)structure and vascular function.

NCT ID: NCT06174870 Not yet recruiting - Hypertension Clinical Trials

The Effect of Inspiratory Muscle Training on Blood Pressure and Functional Capacity in Elderly With Hypertension

IMT
Start date: December 10, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate in elderly with hypertension . The main question it aim to answer is: • Investigate the effect of inspiratory muscle training on inspiratory muscle strength, blood pressure and physical capacity Participants will be random in to 2 group and measure baseline. Control group will advise to maintain normal daily life activity. and Intervention group will receive inspiratory muscle training (IMT) with 60% of Maximal inspiratory pressure. Intervention group will perform IMT 30 breaths/day, 5 days a week for 6 weeks. after 6 weeks both group will remeasure variable again as post test